Literature DB >> 12626652

Suppression of cytochrome P450 3A protein levels by proteasome inhibitors.

Richard C Zangar1, Thomas A Kocarek, Shang Shen, Nikki Bollinger, Michael S Dahn, Donna W Lee.   

Abstract

We have previously reported that CYP3A cross-links with polyubiquitinated proteins in microsomes from nicardipine-treated rats in a process that is distinct from classical polyubiquitination. To further examine the role of the proteasome in CYP3A degradation, we investigated the effects of proteasome inhibitors lactacystin, MG132, proteasome inhibitor 1, and hemin in primary cultures of rat and human hepatocytes. With the exception of hemin, these agents increased the total pool of ubiquitinated proteins in microsomes isolated from rat hepatocytes, indicating that lactacystin, MG132, and proteasome inhibitor 1 effectively inhibited the proteasome in these cells. All four agents caused a reduction in the amount of the major approximately 55-kDa CYP3A band, opposite to what would be expected if the ubiquitin-proteasome pathway degraded CYP3A. Only hemin treatment caused an increase in high molecular mass (HMM) CYP3A bands. Because hemin treatment did not alter levels of ubiquitin in CYP3A immunoprecipitates, the HMM CYP3A bands formed in response to hemin treatment clearly were not due to proteasome inhibition. Rather, because hemin treatment also caused an increase in HMM CYP3A in the detergent-insoluble fraction of the 10,000g pellet, the HMM CYP3A seems to represent a large protein complex that is unlikely to primarily represent ubiquitination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626652     DOI: 10.1124/jpet.102.044628

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Identification of ubiquitinated proteins in Arabidopsis.

Authors:  Concepción Manzano; Zamira Abraham; Gema López-Torrejón; Juan C Del Pozo
Journal:  Plant Mol Biol       Date:  2008-06-06       Impact factor: 4.076

2.  Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Authors:  Ying Ou; Yang Xu; Lia Gore; R Donald Harvey; Alain Mita; Kyriakos P Papadopoulos; Zhengping Wang; Richard E Cutler; Dawn E Pinchasik; Apostolia M Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

3.  Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures.

Authors:  Choon-Myung Lee; Jan Pohl; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

4.  Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97?

Authors:  Saadia Faouzi; Katalin F Medzihradszky; Colleen Hefner; Jacquelyn J Maher; Maria Almira Correia
Journal:  Biochemistry       Date:  2007-06-06       Impact factor: 3.162

5.  Hepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinase (PERK) and general control nonderepressible-2 eIF2alpha kinase (GCN2), and global translational shutoff.

Authors:  Poulomi Acharya; Juan C Engel; Maria Almira Correia
Journal:  Mol Pharmacol       Date:  2009-06-11       Impact factor: 4.436

6.  Vitamin D3 May Ameliorate the Ketoconazole Induced Adrenal Injury: Histological and Immunohistochemical Studies on Albino Rats.

Authors:  Mahmoud Salah Khalil
Journal:  Acta Histochem Cytochem       Date:  2015-08-20       Impact factor: 1.938

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.